A Study to Investigate the Neuroprotective Effect of PROCRIT (Epoetin Alfa) Versus Placebo in Cancer Patients Who Develop Chemotherapy-induced Peripheral Neuropathy
Public ClinicalTrials.gov record NCT00267007. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-Blind, Placebo-Controlled, Multicenter, 18 Week Pilot Study to Investigate the Neuroprotective Effect of PROCRIT (Epoetin Alfa) on the Development of Peripheral Neuropathy in Patients Receiving Combination Taxane and Platinum-Based Chemotherapy for Cancer
Study identification
- NCT ID
- NCT00267007
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
- Industry
- Enrollment
- 32 participants
Conditions and interventions
Conditions
Interventions
- PROCRIT 40,000 IU QW Drug
- Placebo Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 31, 2006
- Primary completion
- Jul 31, 2008
- Completion
- Jul 31, 2008
- Last update posted
- Jun 3, 2014
2006 – 2008
United States locations
- U.S. sites
- 28
- U.S. states
- 18
- U.S. cities
- 28
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | Mobile | Alabama | — | — |
| Not listed | Little Rock | Arkansas | — | — |
| Not listed | Alhambra | California | — | — |
| Not listed | Bakersfield | California | — | — |
| Not listed | Fullerton | California | — | — |
| Not listed | La Verne | California | — | — |
| Not listed | Long Beach | California | — | — |
| Not listed | Northridge | California | — | — |
| Not listed | Oxnard | California | — | — |
| Not listed | Santa Maria | California | — | — |
| Not listed | New Haven | Connecticut | — | — |
| Not listed | Hollywood | Florida | — | — |
| Not listed | Augusta | Georgia | — | — |
| Not listed | Joliet | Illinois | — | — |
| Not listed | Indianapolis | Indiana | — | — |
| Not listed | Lexington | Kentucky | — | — |
| Not listed | Bethesda | Maryland | — | — |
| Not listed | Detroit | Michigan | — | — |
| Not listed | Southfield | Michigan | — | — |
| Not listed | Las Vegas | Nevada | — | — |
| Not listed | Lebanon | New Hampshire | — | — |
| Not listed | Buffalo | New York | — | — |
| Not listed | Syracuse | New York | — | — |
| Not listed | Durham | North Carolina | — | — |
| Not listed | Winston-Salem | North Carolina | — | — |
| Not listed | Oklahoma City | Oklahoma | — | — |
| Not listed | Philadelphia | Pennsylvania | — | — |
| Not listed | Chattanooga | Tennessee | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00267007, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 3, 2014 · Synced Jul 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00267007 live on ClinicalTrials.gov.